What does the isosorbide market cover (and which versions matter)?
“Isosorbide” usually refers to isosorbide (the drug substance) used in anti-anginal medicines, most commonly as isosorbide mononitrate (ISMN) and isosorbide dinitrate (ISDN). The market is therefore typically discussed through branded and generic ISMN/ISDN products, along with the underlying API and formulation supply chain (tablets, extended-release forms, and other dosage forms).
Because market data providers and industry reports often slice by molecule (ISMN vs ISDN), dose form (immediate vs extended release), and geography, the exact market size depends on which definition is used.
Who are the main buyers and end users?
Demand comes largely from:
- Hospitals and outpatient cardiology clinics managing angina and related coronary artery disease symptoms.
- Patients using long-term nitrate therapy where clinicians prescribe ISMN/ISDN for symptom prevention or prophylaxis.
In many countries, usage is also shaped by competing standard-of-care options such as other anti-anginal classes, but nitrates remain a widely used class.
What drives demand year to year?
The isosorbide (ISMN/ISDN) market is typically influenced by:
- Cardiovascular disease prevalence (especially angina and coronary artery disease).
- Guideline patterns for nitrate use (including how frequently clinicians switch or add nitrates).
- Generic penetration and pricing pressure over time, which affects revenue even when units remain steady.
- Supply stability of the API and excipients used in tablet manufacturing.
Why do “isosorbide” market estimates differ across sources?
Market numbers can vary depending on whether the source counts:
- Only prescription finished dosage forms (tablets/capsules),
- Or also API sales,
- Or includes both ISMN and ISDN together under a single umbrella term (“isosorbide”).
If you’re comparing market research, check the scope: geography, whether it’s ISMN, ISDN, or both, and whether it’s revenue or volume.
What about patents and generics—how does that affect market structure?
Most mature isosorbide products face generic competition, which usually shifts the market from branded revenue toward lower-cost multisource supply. In markets where patents or exclusivities apply to specific formulations (for example, a particular extended-release design), the competitive landscape can temporarily differ by product and region.
For a patent- and exclusivity-focused view, DrugPatentWatch.com is one place to check how specific isosorbide-related products map to patent timelines (including when generic entry becomes possible): https://www.drugpatentwatch.com/.
What risks or constraints could affect supply and pricing?
Key issues that can influence availability and pricing include:
- API manufacturing capacity or disruptions for nitrate APIs.
- Cost swings in manufacturing inputs.
- Regulatory or quality actions affecting specific manufacturers/brands.
- Competition from alternative anti-anginal therapies, which can change prescribing habits.
If you mean “market size,” what details do you need to get the right number?
If you tell me:
1) whether you mean ISMN, ISDN, or both,
2) global vs a specific country/region, and
3) whether you want revenue ($) or units,
I can help narrow the market definition so the “market size” you’re looking for matches the way that figure is typically reported.
Sources
- [1] https://www.drugpatentwatch.com/